z-logo
Premium
Mirabegron the first β 3 ‐adrenoceptor agonist for overactive bladder ( OAB ): a summary of the phase III studies
Author(s) -
Chapple Christopher
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12773
Subject(s) - mirabegron , tolterodine , overactive bladder , placebo , medicine , tolerability , discontinuation , urology , agonist , pharmacology , adverse effect , receptor , alternative medicine , pathology

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom